摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-bromophenyl)-5-methylfuran | 159448-54-1

中文名称
——
中文别名
——
英文名称
2-(2-bromophenyl)-5-methylfuran
英文别名
——
2-(2-bromophenyl)-5-methylfuran化学式
CAS
159448-54-1
化学式
C11H9BrO
mdl
——
分子量
237.096
InChiKey
KZDAYTAAKAAKNR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    13.1
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    2-(2-bromophenyl)-5-methylfuran正丁基锂CO2 作用下, 以 四氢呋喃正己烷 为溶剂, 以95%的产率得到2-(5-甲基-2-呋喃基)苯甲酸
    参考文献:
    名称:
    Imidazole ethers having a II antagonist activity
    摘要:
    通式(I)的化合物##STR1##其中E为O或S;R为C.sub.1-C.sub.5直链、支链或环烷基或C.sub.2-C.sub.5烯基;X可以是H、F、Cl、Br、I、CF.sub.3;n为1到4的整数;m为0到4的整数;A和B为5-或6-成员芳香碳环,可选地含有来自N、O、S的一个或多个杂原子,并携带取代基R.sub.1、R.sub.2和R.sub.3,分别;R.sub.1可以是氢、卤素、C.sub.1-C.sub.4烷氧羰基、磺酰基或式的四唑基团##STR2##其中R.sub.4可以是氢或C.sub.1-C.sub.5烷基;R.sub.2可以是氢或COOR.sub.4基团(其中R.sub.4为氢或C.sub.1-C.sub.5烷基)、CN、SO.sub.3 H、PO.sub.3 H或四唑基团R.sub.3;可以是氢或式的一个基团(II)B'(R'.sub.2,R'.sub.3)(II)其中:B.sup.1,R.sup.1.sub.2具有上述B和R.sub.2的相同含义,R'.sub.3为H;但条件是当A为苯时,R.sub.1不同于H,及其药学上可接受的盐。
    公开号:
    US05538987A1
  • 作为产物:
    描述:
    1-(2-bromo-phenyl)-pentane-1,4-dionesilica gel 对甲苯磺酸 作用下, 以 为溶剂, 以70%的产率得到2-(2-bromophenyl)-5-methylfuran
    参考文献:
    名称:
    Imidazole ethers having a II antagonist activity
    摘要:
    通式(I)的化合物##STR1##其中E为O或S;R为C.sub.1-C.sub.5直链、支链或环烷基或C.sub.2-C.sub.5烯基;X可以是H、F、Cl、Br、I、CF.sub.3;n为1到4的整数;m为0到4的整数;A和B为5-或6-成员芳香碳环,可选地含有来自N、O、S的一个或多个杂原子,并携带取代基R.sub.1、R.sub.2和R.sub.3,分别;R.sub.1可以是氢、卤素、C.sub.1-C.sub.4烷氧羰基、磺酰基或式的四唑基团##STR2##其中R.sub.4可以是氢或C.sub.1-C.sub.5烷基;R.sub.2可以是氢或COOR.sub.4基团(其中R.sub.4为氢或C.sub.1-C.sub.5烷基)、CN、SO.sub.3 H、PO.sub.3 H或四唑基团R.sub.3;可以是氢或式的一个基团(II)B'(R'.sub.2,R'.sub.3)(II)其中:B.sup.1,R.sup.1.sub.2具有上述B和R.sub.2的相同含义,R'.sub.3为H;但条件是当A为苯时,R.sub.1不同于H,及其药学上可接受的盐。
    公开号:
    US05538987A1
点击查看最新优质反应信息

文献信息

  • AgONO-Assisted Direct CH Arylation of Heteroarenes with Anilines
    作者:Saravanan Gowrisankar、Jayasree Seayad
    DOI:10.1002/chem.201403640
    日期:2014.9.26
    A novel copper‐catalyzed CH arylation of heteroarenes with anilines by an in situ diazonium reaction is established by using silver nitrite (AgONO) as an unconventional nitrosating reagent under acid‐free conditions. It provides a complementary approach for the CH arylation of electronrich heteroarenes with aromatic amines affording a variety of heterobiaryls in moderate to good yields.
    一种新颖的催化Ç 芳基化与苯胺通过原位重氮反应通过使用亚硝酸银(AgONO)作为无酸的条件下一个非常规的亚硝基化试剂建立杂芳烃小时。它为富电子杂芳基与芳族胺的C芳基化提供了一种补充方法,该芳族胺以中等至良好的收率提供了各种杂二芳基。
  • 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
    申请人:Tsubouchi Hidetsugu
    公开号:US20060094767A1
    公开(公告)日:2006-05-04
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.
    本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物,其通式如下:其中,R1代表氢原子或C1-C6烷基,n代表0到6的整数,R2代表—OR3或类似的基团,R3代表氢原子、C1-C6烷基或类似的基团,或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环,其通式为(H):其中,R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
  • 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP1555267A1
    公开(公告)日:2005-07-20
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group -OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and -(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and a typical acid-fast bacteria.
    本发明提供了由以下通式代表的 2,3-二氢-6-硝基咪唑并[2,1-b]恶唑化合物: 其中R1代表氢原子或C1-C6烷基,n代表0至6的整数,R2代表基团-OR3或类似基团,R3代表氢原子、C1-C6烷基或类似基团,或者R1和-(CH2)nR2可以通过氮原子与相邻的碳原子相互结合,从而形成通式(H)代表的螺环: 其中 R41 为氢、C1-C6 烷基或类似基团。本化合物对结核分枝杆菌、多重耐药结核分枝杆菌和典型的耐酸细菌有很好的杀菌作用。
  • 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP2570418A2
    公开(公告)日:2013-03-20
    The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group -OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and -(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.
    本发明提供了一种由以下通式表示的 2,3-二氢-6-硝基咪唑并[2,1-b]恶唑化合物: 其中R1代表氢原子或C1-C6烷基,n代表0至6的整数,R2代表基团-OR3或类似基团,R3代表氢原子、C1-C6烷基或类似基团,或者R1和-(CH2)nR2可以通过氮原子与相邻的碳原子相互结合,从而形成通式(H)代表的螺环: 其中 R41 为氢、C1-C6 烷基或类似基团。本化合物对结核分枝杆菌、多重耐药结核分枝杆菌和非典型耐酸菌有很好的杀菌作用。
  • Nonpeptide Angiotensin II Receptor Antagonists. Synthesis, in vitro Activity, and Molecular Modeling Studies of N-[(Heterobiaryl)methyl]imidazoles
    作者:Aldo Salimbeni、Renato Canevotti、Fabio Paleari、Fabrizio Bonaccorsi、Anna R. Renzetti、Laura Belvisi、Gianpaolo Bravi、Carlo Scolastico
    DOI:10.1021/jm00049a012
    日期:1994.11
    With the aim of explaining the influence of the structural changes on the biphenylic moiety on the activity, a series of N-[(heterobiaryl)methyl]imidazoles (I), constructed on the model of DuPont compounds by replacing either the central or terminal phenyl ring with a heteroaromatic one, such as furan, thiophene, thiazole, and pyridine, was synthesized. Compared to the reference DuPont compound (EXP-7711), all the heterobiaryl derivatives showed a reduced potency both in receptor binding (rat adrenal capsular membranes) and in the functional assay (angiotensin II-induced contraction of rabbit aorta strips). The lower activity was justified by the extensive molecular modeling studies, which took into consideration the conformational and electrostatic features of several heterobiaryl derivatives. On the basis of the results obtained, it was hypothesized that the central aromatic ring of the biarylic portion works as a spacer, orienting in the right way the terminal phenyl ring, whose electronic distribution is, instead, crucial to its fitting well with a lipophilic pocket at the receptor site.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫